Videos

Anne E. Winkler, MD, PhD, MACP shares her approach to treatment in patients with lupus post treatment with immunosuppressants with a focus on treatment sequencing.

Drs Anne E. Winkler and Kristi V. Mizelle explore relevant treatment options for a patient with lupus nephritis and highlight efficacy and safety considerations.

Terence Rooney, MD, discusses the ongoing STAR study in depth and the potential of guselkumab to improve axial psoriatic arthritis.

An expert in lupus management provides insight into her treatment approach for a 24-year-old African American female diagnosed with lupus nephritis.

Lupus Case Scenario: Patient History and Presentation

The highly encouraging results of the small study may lead to a new therapeutic approach in lupus. However, long-term safety and efficacy need to be evaluated in a larger cohort.

Drs Orrin M. Troum and Jeff R. Peterson discuss infusion reactions associated with pegloticase and the impact of immunomodulators when used with pegloticase in gout.

Orrin M. Troum, MD, and Jeff R. Peterson, MD, discuss challenges with gout treatment.

Orrin M. Troum, MD, discusses methods and results of the MIRROR study in gout.

The Rheumatology Research Foundation has recently announced a grant, called the Community Practice Innovation Award, which focuses on supporting rheumatology practitioners to conduct their crucial, and potentially life-changing, research.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, address the importance of clinician confidence in biosimilars.

Anne E. Winkler, MD, PhD, MACP and Kristi V. Mizelle, MD, MPH, FACR hypothesize about the role and future of a treat to target approach in patients with lupus.

Kristi V. Mizelle, MD, MPH, FACR shares her treatment goals and discusses the patient characteristics she factors when deciding on a choice of treatment for her patients.

Orrin M. Troum, MD, discusses the background to the MIRROR study in gout.

Orrin M. Troum, MD, and Jeff R. Peterson, MD, discuss burden, treatment landscape, and unmet needs in gout.

Dr. John Botson explains that gout is not a patient problem, it's a disease problem, and it needs to be approached as a lifelong rheumatic disease as opposed to an episodic one.

Investigator Dr. John Botson spoke on the phase 4 MIRROR study that supported the FDA approval for pegloticase combined with methotrexate for patients with uncontrolled gout.

John K. Botson MD, RPh, CCD, weighs in on the recent FDA approval of pegloticase injection plus methotrexate for the treatment of uncontrolled gout.

Iwasaki and her team analyzed 3220 unique sequences of endogenous retroviruses that are a part of the human genetic make up or genome to understand if retroviruses cause or worsen this disease.

Expert Michael Aziz discusses clinical complications that patients face when they become pregnant as well as the importance of medication management and abortion care.

David Felson, MD, MPH, discusses his recent study, “Meaning of patient global assessment when joint counts are low in rheumatoid arthritis.”

Previous attempts to make associations between JIA and prenatal maternal infection is difficult due to the rarity of JIA diagnosis and recall bias.

Dr. Philip Mease explains that it's a good time to be treating psoriatic arthritis after results from a clinical trial show that guselkumab provided continuous improvement across measures of health-related quality of life.

With guselkumab, patients with active psoriatic arthritis achieved efficacy that was sustained through a 2 year clinical trial. Results show that the treatment offered continuous improvement across measures of health-related quality of life.

Take a few minutes to check out Rheumatology Network's top expert interviews from Q2 2022.

Frédéric Lavie, MD, PhD, explains the results of the data presented at EULAR evaluating guselkumab for the treatment of psoriatic arthritis.

Terence Rooney, MD, explains the innovative research methods that Janssen utilizes and the benefits of precision medicine in the treatment of psoriatic arthritis.

Terence Rooney, MD, discusses recent findings indicating that guselkumab provided patients with psoriatic arthritis with sustained improvements in health-related quality of life through 2 years.

Massimo Radin, MD, PhD, explains how tailoring oral therapy in rheumatoid arthritis, via the TuTOR App, can improve medication adherence.

James Woody, MD, PhD, explains the benefits of treating Dupuytren’s disease with anti-tumor necrosis factor (TNF).